Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Wang, Hui, Zhang, Yuntao, Huang, Baoying, Deng, Wei, Quan, Yaru, Wang, Wenling, Xu, Wenbo, Zhao, Yuxiu +24 more·2020·Cell
DOI 10.1016/j.cell.2020.06.008

Cited by (749)

Items 101–200 of 749

  1. An Overview of Vaccine Development for COVID-19
    Seyed Hossein Shahcheraghi, Jamshid Ayatollahi, Alaa A. A. Aljabali, Madhur D. Shastri, Shakti Dhar Shukla, Dinesh K Chellappan, Niraj Kumar Jha, Krishnan Anand, Naresh Kumar Katari, Meenu Mehta et al. · 2021 · Therapeutic Delivery
  2. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies
    L. Kozlovskaya, A. Piniaeva, G. Ignatyev, I. Gordeychuk, V. Volok, Y. V. Rogova, A. Shishova, A. Kovpak, Y. Ivin, L. Antonova et al. · 2021 · Emerging Microbes and Infections
  3. Advances in the design and development of SARS-CoV-2 vaccines
    Xue‐Liang Peng, Ji‐Si‐Yu Cheng, Hai‐Lun Gong, Meng-Di Yuan, Xiaohong Zhao, Zibiao Li, Dai‐Xu Wei · 2021 · Military Medical Research
  4. SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines
    John E. Bowen, Young‐Jun Park, Cameron Stewart, Jack T Brown, William K. Sharkey, Alexandra C. Walls, Anshu Joshi, Kaitlin R. Sprouse, Matthew McCallum, M. Alejandra Tortorici et al. · 2022 · Science Immunology
  5. Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses
    Cillian Gartlan, Tom Tipton, Francisco Javier Salguero, Quentin James Sattentau, Andrew R. GORRINGE, Miles W. Carroll · 2022 · Frontiers in Immunology
  6. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients
    Hannah M. Kelly, Brent S. Sokola, Hesham Abboud · 2021 · Journal of Neuroimmunology
  7. Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination
    Haya Altawalah · 2021 · Vaccines
  8. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP
    Laura Solforosi, Harmjan Kuipers, Mandy A. C. Jongeneelen, Sietske K. Rosendahl Huber, Joan E. M. van der Lubbe, Liesbeth Dekking, Dominika N. Czapska-Casey, Ana Izquierdo Gil, Miranda R.M. Baert, Joke Drijver et al. · 2021 · The Journal of Experimental Medicine
  9. Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies
    Qi Xiang, Linhao Li, Jie Wu, Miao Tian, Yang Fu · 2022 · Microbiological Research
  10. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines
    Baoying Huang, Lianpan Dai, Hui Wang, Zhongyu Hu, Xiaoming Yang, Wenjie Tan, George F. Gao · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  11. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model
    Mohandas, Sreelekshmy, Yadav, Pragya D., Shete-Aich, Anita, Abraham, Priya, Vadrevu, Krishna Mohan, Sapkal, Gajanan, Mote, Chandrashekhar, Nyayanit, Dimpal, Gupta, Nivedita, Srinivas, Vellimedu Kannappa et al. · 2021 · iScience
  12. Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects
    Zhan Zhang, Qi Shen, Haocai Chang · 2022 · Frontiers in Immunology
  13. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
    J. Francica, Barbara Flynn, K. Foulds, Amy T. Noe, Anne P. Werner, Ian N. Moore, M. Gagne, T. Johnston, C. Tucker, Rachel L. Davis et al. · 2021 · Science Translational Medicine
  14. Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding
    Jakob Trimpert, Kristina Dietert, Theresa C. Firsching, Nadine Ebert, Tran Thi Nhu Thao, Daria Vladimirova, Susanne Kaufer, Fabien Labroussaa, Azza Abdelgawad, Andelé M. Conradie et al. · 2021 · Cell Reports
  15. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
    He, Xuan, Chandrashekar, Abishek, Zahn, Roland, Wegmann, Frank, Yu, Jingyou, Mercado, Noe B., McMahan, Katherine, Martinot, Amanda J., Piedra-Mora, Cesar, Beecy, Sidney et al. · 2021 · Cell
  16. Animal models for SARS-CoV-2
    Chung-Young Lee, Anice C. Lowen · 2021 · Current Opinion in Virology
  17. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study
    Yanmeng Feng, Yifan Zhang, Zhangyufan He, Haojie Huang, Xiangxiang Tian, Gang Wang, Daihong Chen, Yanqin Ren, Liqiu Jia, Wanhai Wang et al. · 2021 · EClinicalMedicine
  18. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 Vaccines
    Tomabu Adjobimey, Julia Meyer, Leander Sollberg, Michael Bawolt, Christina Berens, Peđja Kovačević, Anika Trudić, Marijo Parčina, Achim M. Hoerauf · 2022 · Frontiers in Immunology
  19. Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
    Ping Yuan, Pu Ai, Yihan Liu, Zisheng Ai, Yi Wang, Weijun Cao, Xiaohuan Xia, Jialin Zheng · 2020 · SSRN Electronic Journal
  20. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting
    Ziwei Li, Tiandan Xiang, Boyun Liang, Hui Deng, Hua Wang, Xuemei Feng, Xufeng Quan, Xiaoyan Wang, Sumeng Li, Sihong Lu et al. · 2021 · Frontiers in Immunology
  21. Inhibition of Autophagy Suppresses SARS-CoV-2 Replication and Ameliorates Pneumonia in hACE2 Transgenic Mice and Xenografted Human Lung Tissues
    Chao Shang, Xinyu Zhuang, He Zhang, Yiquan Li, Yilong Zhu, Jing Lu, Chenchen Ge, Jianan Cong, Tingyu Li, Nan Li et al. · 2021 · Journal of Virology
  22. Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects
    Zhongbiao Fang, Jingting Lyu, Jianhua Li, Chaonan Li, Yuxuan Zhang, Yikai Guo, Ying Wang, Yanjun Zhang, Keda Chen · 2022 · Frontiers in Bioengineering and Biotechnology
  23. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world
    Vivek P. Chavda, Qian Yao, Lalitkumar K. Vora, Vasso Apostolopoulos, Chirag Amrutlal Patel, Rajashri Bezbaruah, Aayushi Patel, Zhe‐Sheng Chen · 2022 · Frontiers in Immunology
  24. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
    Suvichada Assawakosri, Sitthichai Kanokudom, Nungruthai Suntronwong, Chompoonut Auphimai, Pornjarim Nilyanimit, Preeyaporn Vichaiwattana, Thanunrat Thongmee, Thaneeya Duangchinda, Warangkana Chantima, Pattarakul Pakchotanon et al. · 2022 · The Journal of Infectious Diseases
  25. COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform
    Muhammad Umer Ashraf, Yeji Kim, Sunil Kumar, Dongyeob Seo, Maryam Ashraf, Yong‐Soo Bae · 2021 · Vaccines
  26. Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization
    Yongjun Sui, Yonas Bekele, Jay A. Berzofsky · 2021 · Pathogens
  27. SARS-CoV-2: vaccines in the pandemic era
    Dandan Li, Qihan Li · 2021 · Military Medical Research
  28. Impact of the Sinopharm’s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)
    Farida Ismail Al Hosani, Anderson Eduardo Stanciole, Bashir Aden, Andrey Timoshkin, Omar Najim, Walid Abbas Zaher, Fatima AlSayedsaleh AlDhaheri, Shereena Al Mazrouie, Tahir Aziz Rizvi, Farah Mustafa · 2021 · Vaccine
  29. Emerging SARS-CoV-2 variants: Why, how, and what's next?
    Yu Zheng Chen, Qianyun Liu, Li Zhou, You Zhou, Huan Yan, Ke Lan · 2022 · Cell Insight
  30. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco
    Yaowen Zhang, Jihane Belayachi, Yunkai Yang, Qiang Fu, Lance Everett Rodewald, Hongling Li, Bing Yan, Ying Wang, Yanna Shen, Qian Yang et al. · 2022 · BMC Public Health
  31. Animal coronaviruses and SARS‐CoV‐2
    Guangzhi Zhang, Bin Li, Dongwan Yoo, Tong Qin, Xiaodong Zhang, Yaxiong Jia, Shangjin Cui · 2020 · Transboundary and Emerging Diseases
  32. Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2
    Nilesh Gajanan Bajad, Rayala Swetha, Gopichand Gutti, Anjali Sharma, Meenakshi Singh, Ashok Kumar, Sushil Kumar Singh · 2021 · Current Research in Pharmacology and Drug Discovery
  33. Safety and potency of BIV1‐CovIran inactivated vaccine candidate for SARS‐CoV‐2: A preclinical study
    Asghar Abdoli, Reza Aalizadeh, Hossein Aminianfar, Zahra Kianmehr, Ali Teimoori, Ebrahim Azimi, Nabbi Emamipour, Marzieh Eghtedardoost, Vahid Siavashi, Hamidreza Jamshidi et al. · 2021 · Reviews in Medical Virology
  34. Delivery Routes for COVID-19 Vaccines
    J. Park, H. Lee · 2021 · Vaccines
  35. Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine
    Christopher L. D. McMillan, Jovin J. Y. Choo, Adi Idris, Aroon Supramaniam, Naphak Modhiran, Alberto Anastacio Amarilla, Ariel Isaacs, Stacey T. M. Cheung, Benjamin Liang, Helle Bielefeldt‐Ohmann et al. · 2021 · Science Advances
  36. COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response
    Swati Jain, Himanshu Batra, Poonam Yadav, Subhash Chand · 2020 · Vaccines
  37. Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment
    Sameer Kumar Malladi, Randhir Singh, Suman Pandey, Savitha Gayathri, Kawkab Kanjo, Shahbaz Ahmed, M. S. A. Alam Khan, Parismita Kalita, Nidhi Girish, Aditya Upadhyaya et al. · 2020 · Journal of Biological Chemistry
  38. Modelling the DFT structural and reactivity study of feverfew and evaluation of its potential antiviral activity against COVID-19 using molecular docking and MD simulations
    Shradha Lakhera, Kamal Devlal, Arabinda Ghosh, Papia Chowdhury, Meenakshi M. Rana · 2022 · Chemical Papers
  39. Innovations and development of Covid-19 vaccines: A patent review
    Ahmed Subeh Alshrari, Shuaibu Abdullahi Hudu, Mohd Imran, Syed Mohammed Basheeruddin Asdaq, Mateq Ali Alreshidi, Syed Imam Rabbani · 2021 · Journal of Infection and Public Health
  40. Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape
    André E. Nel, Jeff F. Miller · 2021 · ACS Nano
  41. Design and application of nanoparticles as vaccine adjuvants against human corona virus infection
    Lichun Mao, Ziwei Chen, Yaling Wang, Chunying Chen · 2021 · Journal of Inorganic Biochemistry
  42. On the road to ending the COVID-19 pandemic: Are we there yet?
    J. Case, Emma S. Winkler, J. Errico, Michael S. Diamond · 2021 · Virology
  43. Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys
    Hassan Alkharaan, Shaghayegh Bayati, Cecilia Hellström, Soo Aleman, Annika Olsson, Karin Lindahl, Gordana Bogdanović, Katie Healy, Georgios Tsilingaridis, Patricia Palma et al. · 2021 · The Journal of Infectious Diseases
  44. Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn
    Mehdi Shahgolzari, Afagh Yavari, Yaser Arjeini, Seyed Mohammad Miri, Amirhossein Darabi, Amir Sasan Mozaffari Nejad, Mohsen Keshavarz · 2021 · Gene Reports
  45. Cryo-electron Microscopy Structure of S-Trimer, a Subunit Vaccine Candidate for COVID-19
    Jiahao Ma, Danmei Su, Yinyan Sun, Xueqin Huang, Ying Shi Liang, Linqiang Fang, Yan Ma, Wenhui Li, Peng Liang, Sanduo Zheng · 2021 · Journal of Virology
  46. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques
    Neeltje van Doremalen, Jyothi N. Purushotham, Jonathan E. Schulz, Myndi G. Holbrook, Trenton Bushmaker, Aaron Carmody, Julia Rebecca Port, Claude Kwe Yinda, Atsushi Okumura, Greg A. Saturday et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  47. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance
    Lirong Cao, Jingzhi Lou, See Yeung Chan, Hong Zheng, Caiqi Liu, Shi Zhao, Qi Li, Chris Ka Pun Mok, Renee W. Y. Chan, Ka Chun Chong et al. · 2022 · Nature Medicine
  48. Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial
    Yuyi Liao, Yuan Li, Rongjuan Pei, Xin De Fang, Peiyu Zeng, Renfeng Fan, Zhiqiang Ou, Jinglong Deng, Jian Zhou, Wuxiang Guan et al. · 2021 · Emerging Microbes & Infections
  49. Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021
    Kun Xu, Lianpan Dai, George F. Gao · 2021 · International Immunology
  50. Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization
    Zhangkai Jason Cheng, Huimin Huang, Peiyan Zheng, Mingshan Xue, Jing Ma, Zhiqing Zhan, Hui Gan, Yifeng Zeng, Runpei Lin, Shiyun Li et al. · 2022 · Allergy
  51. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models
    Runhong Zhou, Pui Wang, Yik-Chun Wong, Haoran Xu, Siu-Ying Lau, Li Liu, Bobo Wing-Yee Mok, Qiaoli Peng, Na Liu, Kin Fai Woo et al. · 2021 · EBioMedicine
  52. Temporal Strategies and Firms’ Speedy Responses to COVID‐19
    David Ahlström, Linda C. Wang · 2020 · Journal of Management Studies
  53. Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness
    Esmaeil Mehraeen, Omid Dadras, Amir Masoud Afsahi, Amirali Karimi, Mehrzad MohsseniPour, Pegah Mirzapour, Alireza Barzegary, Farzane Behnezhad, Pedram Habibi, Mohammad Amin Salehi et al. · 2021 · Infectious Disorders - Drug Targets
  54. COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations
    Zhipeng Yan, Ming Yang, Ching‐Lung Lai · 2021 · Vaccines
  55. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications
    Lijun Chen, Jingjing Qu, Farhin Shaheed Kalyani, Qi Zhang, Lingzhi Fan, Yangxin Fang, Yifei Li, Charlie Xiang · 2022 · Cellular and Molecular Life Sciences
  56. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
    Mohd Zulkifli Salleh, Mohd Nor Norazmi, Zakuan Zainy Deris · 2022 · PeerJ
  57. Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity
    Balamurugan Shanmugaraj, Narach Khorattanakulchai, Chalisa Panapitakkul, Ashwini Malla, Rawiwan Im‐Erbsin, Manutsanun Inthawong, Piyanate Sunyakumthorn, Taweewun Hunsawong, Chonticha Klungthong, Matthew C. Reed et al. · 2022 · Vaccine
  58. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
    Yubin Liu, Ziyi Wang, Xinyu Zhuang, Shengnan Zhang, Zhicheng Chen, Yan Zou, Jie Sheng, Tianpeng Li, Wanbo Tai, Jinfang Yu et al. · 2023 · Nature Communications
  59. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial
    Nawal Ahmed Mohamed Al Kaabi, Yun Kai Yang, Li Fang Du, Ke Xu, Shuai Shao, Yu Liang, Yun Kang, Ji Guo Su, Jing Zhang, Tian Yang et al. · 2022 · Nature Communications
  60. Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
    Ahmed Kandeil, Ahmed Mostafa, Rehab R. Hegazy et al. · 2021 · Vaccines
  61. Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2
    Shafi Mahmud, Gobindo Kumar Paul, Suvro Biswas, Shamima Afrose, Mohasana Akter Mita, Md. Robiul Hasan, Mst. Sharmin Sultana Shimu, Alomgir Hossain, Maria Meha Promi, FAHMIDA KHAN EMA et al. · 2021 · Frontiers in Molecular Biosciences
  62. Immune responses to Sinopharm/ BBIBP‐CorV in individuals in Sri Lanka
    Chandima Jeewandara, Inoka Sepali Aberathna, Pradeep Darshana Pushpakumara, Achala Kamaladasa, Dinuka Guruge, Ayesha Wijesinghe, Banuri Gunasekera, Shyrar Tanussiya, Heshan Kuruppu, Thushali Ranasinghe et al. · 2022 · Immunology
  63. COVID-19: comprehensive review on mutations and current vaccines
    Ananda Vardhan Hebbani, Swetha Pulakuntla, Padmavathi Pannuru, Sreelatha Aramgam, Kameswara Rao Badri, Vaddi Damodara Reddy · 2021 · Archives of Microbiology
  64. Classification of five SARS-CoV-2 serotypes based on RBD antigenicities
    Shixiong Hu, Chunli Wu, Xinkai Wu, Xuehui Ma, Chang Shu, Qian Chen, Anqi Zheng, Huiting Yang, Jian Lü, Pei Du et al. · 2023 · 中国科学通报：英文版
  65. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza
    Man Xing, Gaowei Hu, Xiang Wang, Yihan Wang, Furong He, Weiqian Dai, Xinyu Wang, Yixin Niu, Jiaojiao Liu, Hui Liu et al. · 2024 · npj Vaccines
  66. SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals
    Shota Yoshida, Chikako Ono, Hiroki Hayashi, Shinya Fukumoto, Satoshi Shiraishi, Kazunori Tomono, Hisashi Arase, Yoshiharu Matsuura, Hironori Nakagami A · 2021 · Scientific Reports
  67. Vaccines platforms and COVID-19: what you need to know
    Isabel Acosta-Coley, Leonor Cervantes-Ceballos, Lesly Patricia Tejeda Benítez, Lucellys Sierra-Marquez, María Cabarcas-Montalvo, María Cecilia García Espiñeira, Wilfrido Coronell-Rodríguez, Bárbara Arroyo-Salgado · 2022 · Tropical Diseases Travel Medicine and Vaccines
  68. Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine
    Bo Tang, Li Tang, Wei He, Xingyu Jiang, Chang-jiang Hu, Yicheng Li, Yang Zhang, Kun Pang, Yuanyuan Lei, Shengpeng Li et al. · 2022 · Cell Reports Medicine
  69. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity
    J. Chaudhary, R. Yadav, P. Chaudhary, Anurag Maurya, Nimita Kant, O. Al Rugaie, H. Haokip, Deepika Yadav, Rakesh P. N. Roshan, R. Prasad et al. · 2021 · Cells
  70. Phage Display-Derived Peptide for the Specific Binding of SARS-CoV-2
    Fan Yang, Li Liu, Pierre Fernand Neuenschwander, Steven Idell, Ramakrishna Vankayalapati, Krishan Gopal Jain, Ke Du, Hong‐Long Ji, Guohua Yi · 2021 · ACS Omega
  71. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants
    Zhen-Lin Yang, Yulu Wang, Yu-jia Jin, Yuan-Fei Zhu, Yan-Ling Wu, Cheng Li, Yu Kong, Wen-Ping Song, Xiaolong Tian, Wuqiang Zhan et al. · 2021 · Signal Transduction and Targeted Therapy
  72. Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy
    Ming‐liang Ma, Dawei Shi, Yang Li, Wei Hong, Dan‐yun Lai, Jun‐biao Xue, He‐wei Jiang, Hainan Zhang, Huan Qi, Qingfeng Meng et al. · 2021 · Cell Discovery
  73. Immune Response to SARS-CoV-2 Vaccines
    Navya Bellamkonda, Upendra Pradeep Lambe, Sonali Ankush Sawant, Shyam Sundar Nandi, Chiranjib Chakraborty, Deepak Shukla · 2022 · Biomedicines
  74. Nanomedicine for drug resistant pathogens and COVID-19 using mushroom nanocomposite inspired with bacteriocin – A review
    Moovendran Srinivash, Raman Krishnamoorthi, Pambayan Ulagan Mahalingam, Balasubramanian Malaikozhundan, Subramanian Bharathakumar, K. Gurushankar, Kalyani Dhanapal, Kasi Karuppa Samy, Anand Babu Perumal · 2023 · Inorganic Chemistry Communications
  75. SARS-CoV-2 immunity in animal models
    Zhaoming Chen, Yaochang Yuan, Qingtao Hu, Ai-Ru Zhu, Fenghua Chen, Shu Li, Xin Guan, Chao Lv, Tian Tang, Yi-Yun He et al. · 2024 · Cellular & Molecular Immunology
  76. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
    Gisela Canedo-Marroquín, Farides Saavedra, Catalina A. Andrade, Roslye V. Berríos-Rojas, Linmar Rodríguez‐Guilarte, María Cecilia Opazo, Claudia A. Riedel, Alexis M. Kalergis · 2020 · Frontiers in Immunology
  77. Development of an Inactivated Vaccine against SARS CoV-2
    Shaikh Terkıs Islam Pavel, Hazel Yetişkin, Muhammet Ali Uygut, Ahmet Furkan Aslan, Günsu Aydın, Öznur İnan, Büşra Kaplan, Aykut Özdarendeli · 2021 · Vaccines
  78. Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview
    Omid Gholizadeh, Saman Yasamineh, Parya Amini, Hamed Afkhami, Abbasali Delarampour, Sama Akbarzadeh, Rasool Karimi Matloub, Mahlagha Zahedi, Parastoo Hosseini, Mehrnaz Hajiesmaeili et al. · 2022 · Virology Journal
  79. The Current Status of COVID-19 Vaccines
    Kenneth H. Lundstrom · 2020 · Frontiers in Genome Editing
  80. A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques
    Paul E. Harris, Trevor Brasel, Christopher Massey, C.v. Herst, Scott Burkholz, Peter M. Lloyd, Tikoes Blankenberg, Thomas M. Bey, Richard T. Carback, Thomas W Hodge et al. · 2021 · Vaccines
  81. An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
    Zezhong Liu, Wei Xu, Zhenguo Chen, Wangjun Fu, Wuqiang Zhan, Yidan Gao, Jie Zhou, Yunjiao Zhou, Jianbo Wu, Qian Wang et al. · 2021 · Protein & Cell
  82. Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates
    Nawal Ahmed Mohamed Al Kaabi, Abderrahim Oulhaj, Subhashini Ganesan, Farida Ismail Al Hosani, Omar Najim, Halah Ibrahim, Juan Manuel Acuna, Ahmed R. Alsuwaidi, Ashraf Mohamed Kamour, Ashraf Hassan Alzaabi et al. · 2022 · Nature Communications
  83. RETRACTED: Toxicity of spike fragments SARS-CoV-2 S protein for zebrafish: A tool to study its hazardous for human health?
    Bianca Helena Ventura Fernandes, Natália Martins Feitosa, Ana Paula Barbosa, Camila Gasque Bomfim, Anali M. B. Garnique, Ivana Felipe da Rosa, Maira da Silva Rodrigues, Lucas B. Doretto, Daniel Fernandes da Costa, Bruno Camargo-Dos-Santos et al. · 2021 · The Science of The Total Environment · Retracted
  84. Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination
    Eng Eong Ooi, Arti Dhar, Richard A. Petruschke, Camille Locht, Philippe Buchy, Jenny Guek Hong Low · 2022 · npj Vaccines
  85. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients
    Jira Chansaenroj, Ritthideach Yorsaeng, Jiratchaya Puenpa, Nasamon Wanlapakorn, Chintana Chirathaworn, Natthinee Sudhinaraset, Manit Sripramote, Piti Chalongviriyalert, Supunee Jirajariyavej, Phatharaporn Kiatpanabhikul et al. · 2022 · PLoS ONE
  86. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial
    Nawal Al Kaabi, Yun Kai Yang, Jing Zhang, Ke Xu, Yu Liang, Yun Kang, Ji Guo Su, Tian Yang, Salah Eldin Hussein, Mohamed Saif ElDein et al. · 2022 · Signal Transduction and Targeted Therapy
  87. Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity
    Fuhua Wu, Shuang Luo, Yongshun Zhang, Yangsen Ou, Hairui Wang, Zhaofei Guo, Chun‐Ting He, Shuting Bai, Penghui He, Min Jiang et al. · 2022 · Acta Pharmaceutica Sinica B
  88. Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
    J. Francica, Barbara Flynn, K. Foulds, Amy T. Noe, Anne P. Werner, Ian N. Moore, M. Gagne, T. Johnston, C. Tucker, Rachel L. Davis et al. · 2021 · bioRxiv
  89. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates
    Labanya Mukhopadhyay, Pragya Dhruv Yadav, Nivedita Gupta, Sreelekshmy Mohandas, Deepak Y. Patil, Anita Shete-Aich, Samiran Panda, Balram Bhargava · 2021 · The Indian Journal of Medical Research
  90. What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021
    Jin‐Hong Yoo · 2021 · Journal of Korean Medical Science
  91. MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis
    Bassem Yamout, Magd Fouad Zakaria, Jihad Said Salim Inshasi, Mohammad Al-Jumah, Maya M Zeineddine, Maurice P Dahdaleh, Saeed Bohlega, Riadh Gouider, Raed Alroughani · 2021 · Multiple Sclerosis and Related Disorders
  92. Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque
    Alireza Naderi Sohi, Jafar Kiani, Ehsan Arefian, Arezou Khosrojerdi, Zahra Fekrirad, Shokoofeh Ghaemi, Mohammad Kazem Zim, Arsalan Jalili, Nazila Bostanshirin, Masoud Soleimani · 2021 · Vaccines
  93. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response
    Sally Mahmoud, Subhashini Ganesan, S V Naik, Safaa Bissar, Isra Al Zamel, KN Warren, Walid Abbas Zaher, Gulfaraz Khan · 2021 · Microbiology Spectrum
  94. COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review
    Faizan Zarreen Simnani, Dibyangshee Singh, Ramneet Kaur · 2021 · 3 Biotech
  95. The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
    Yao Jiang, Qian Yun Wu, Peipei Song, Chongge You · 2022 · Frontiers in Medicine
  96. The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic
    Maria Karoliny da Silva Torres, Carlos David Araújo Bichara, Maria de Nazaré do Socorro de Almeida, Mariana Cayres Vallinoto, Maria Alice Freitas Queiroz, Izaura Maria Vieira Cayres Vallinoto, Eduardo José Melo dos Santos, Carlos Alberto Marques de Carvalho, Antônio Carlos Rosário Vallinoto · 2022 · Frontiers in Microbiology
  97. Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies
    Mona Sadeghalvad, Amir Hossein Mansourabadi, Maryam Noori, Seyed Aria Nejadghaderi, Masoomeh Masoomikarimi, Masoumeh Alimohammadi, Nima Rezaei · 2022 · Reviews in Medical Virology
  98. Neutralizing antibodies to SARS‐CoV‐2 variants of concern including Delta and Omicron in subjects receiving mRNA‐1273, BNT162b2, and Ad26.COV2.S vaccines
    George Fei Zhang, Wen Meng, Luping Chen, Ling Ding, Jian Feng, Joseph Pérez, Abid Ali, Shenyu Sun, Zhentao Liu, Yufei Huang et al. · 2022 · Journal of Medical Virology
  99. Current state of, prospects for, and obstacles to mRNA vaccine development
    Alaa A. A. Aljabali, Rasha M. Bashatwah, Mohammad A. Obeid, Vijay Mishra, Yachana Mishra, Ángel Serrano‐Aroca, Kenneth H. Lundstrom, Murtaza M. Tambuwala · 2022 · Drug Discovery Today
  100. Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety
    Hanyan Meng, Jianhua Mao, Qing Ye · 2022 · Journal of Medical Virology